Linfocitos T-CAR en pacientes con mieloma múltiple

María-Victoria Mateos; Verónica González-Call

doi:10.7399/fh.11800

Linfocitos T-CAR en pacientes con mieloma múltiple

María-Victoria Mateos, Verónica González-Call

Resumen

Texto completo:

PDF (English) PDF

Referencias

Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046‑60.

Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(†). Ann Oncol. 2021;32(3):309-22.

Mateos MV, Weisel K, De Stefano V, Perrot A, van de Donk NWCJ, Goldschmidt H, et al. LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma (RRMM) receiving ≥3 prior lines of therapy. J Clin Oncol [Internet]. 2021;39(15_suppl):8041- 8041. DOI: 10.1200/JCO.2021.39.15_suppl.8041

Cho SF, Anderson KC, Tai YT. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Front Immunol. 2018;9:1821.

Munshi NC, Anderson LDJ, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705-16.

Usmani SZ, Berdeja JG, Madduri D, Jakubowiak AJ, Agha ME, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1. J Clin Oncol [Internet]. 2021;39(15_suppl):8005-8005. DOI: 10.1200/JCO.2021.39.15_ suppl.8005

Van de Donk NWCJ, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021;8(6):e446-61.

Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a twoarm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2): 207-21.

Dalla Palma B, Marchica V, Catarozzo MT, Giuliani N, Accardi F. Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma. J Clin Med. 2020;9(9).

DOI: http://dx.doi.org/10.7399%2Ffh.11800